Lupin recalls Cefixime oral suspension: Failed content uniformity
Lup: Cefixime oral suspension (200mg/5mL) with failed content uniformity specifications. Recalled due to potential inconsistent drug levels. No remedy stated in official notice.
Lower-risk recall
Failed Content Uniformity Specifications
Contact the company
What happened, in plain English
Lupin Pharmaceuticals is recalling a specific cefixime oral suspension product because it failed content uniformity tests. This means the medication may not contain the correct amount of active ingredient in each dose, which could affect treatment effectiveness. Read more at govinfonow.com/recall/32640-lupin-recalls-cefixime-oral-suspension-failed-content-uniformity.
Source Summary by GovInfoNow · govinfonow.com/recall/32640-lupin-recalls-cefixime-oral-suspension-failed-content-uniformity · Updated August 18, 2026 · FDA enforcement record: FDA #D-0559-2024
Cite this page
“Lupin recalls Cefixime oral suspension: Failed content uniformity.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/32640-lupin-recalls-cefixime-oral-suspension-failed-content-uniformity. Based on FDA recall #D-0559-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0559-2024%22&limit=1).
Why it’s dangerous
The product failed content uniformity specifications, meaning the medication may not contain the correct amount of active ingredient in each dose. This could lead to inconsistent treatment effectiveness if the patient takes the medication as prescribed.
Who’s affected
Prescription patients who received this specific cefixime oral suspension product. Those with the NDC 68180-407-03 lot F201519 are most at risk.
How to tell if you have this one
Check for the product name 'Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size)' with NDC 68180-407-03 and lot number F201519. This product was manufactured for prescription use only.
- Brand
Lupin- Category
Drug
What to do — step by step
Check Product Details
Identify the NDC 68180-407-03 and lot number F201519 on the product label.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Lupin recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0559-2024 (May 30, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0559-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.